Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference (Virtual) Transcript
All right. Good afternoon, everyone. Welcome to the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst. And it's my pleasure to introduce Ultragenyx and the company's CEO, Emil Kakkis.
And please note that following the presentation, we'll move directly into a Q&A session where you can send in your own questions via the conference portal, and I'll do my best to work these into the conversation.
So Emil, thanks, as always, for joining us. And let me turn things over to you for an update.
Thanks very much, Cory. Good to see you and good to see everyone. I know it's been a busy day and a lot going on, but I'm happy to give you an update on Ultragenyx and where we are today.
If you go past the cover slide, you'll see our legal warning regarding investment in Ultragenyx. And going to the third slide, we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |